98 related articles for article (PubMed ID: 2277209)
1. The current therapeutic approaches to advanced ovarian cancer.
Nishimura H; Hamaguchi K; Miyahara K; Tazaki T; Tateno N; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1691-6. PubMed ID: 2277209
[TBL] [Abstract][Full Text] [Related]
2. [Studies of second-look operations (SLO) in ovarian cancer].
Yuzawa H
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1310-6. PubMed ID: 2658822
[TBL] [Abstract][Full Text] [Related]
3. [Effect of chemotherapy on the prognosis of ovarian cancer].
Sugawa T; Umesaki N; Yajima A; Satoh S; Terashima Y; Ochiai K; Tomoda Y; Kanoh T; Noda K; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Sep; 44(9):1135-41. PubMed ID: 1333504
[TBL] [Abstract][Full Text] [Related]
4. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy.
Bolis G; Villa A; Guarnerio P; Ferraris C; Gavoni N; Giardina G; Melpignano M; Scarfone G; Zanaboni F; Parazzini F
Cancer; 1996 Jan; 77(1):128-31. PubMed ID: 8630918
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; GĂ©rard JP; Romestaing P; Carrie C
Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
[TBL] [Abstract][Full Text] [Related]
6. [The therapeutic value of second-look laparotomy in advanced ovarian carcinoma].
Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
Zentralbl Gynakol; 1988; 110(22):1443-8. PubMed ID: 3223119
[TBL] [Abstract][Full Text] [Related]
7. [Significance of intermittent CDDP therapy for improving long-term prognosis in patients with advanced ovarian cancer].
Umesaki N; Yamamoto A; Nakano M; Matsumoto Y; Tsuda K; Kawabata M; Sugawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Dec; 43(12):1623-30. PubMed ID: 1744459
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of epithelial ovarian carcinoma with cisplatin and adriamycin: analysis of factors influencing prognosis in advanced cases].
Kamura T; Tsukamoto N; Jo S; Imachi M; Kaku T; Matsukuma K; Matsuyama T
Gan To Kagaku Ryoho; 1986 Oct; 13(10):2954-9. PubMed ID: 3021066
[TBL] [Abstract][Full Text] [Related]
9. [The indications for second-look laparotomy in ovarian cancer patients].
Gulo EI; Vinokurov VL; Bokhman IaV
Vopr Onkol; 1992; 38(5):616-23. PubMed ID: 1300762
[TBL] [Abstract][Full Text] [Related]
10. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
11. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors and better survival rate after the treatment of advanced ovarian cancer with neoadjuvant chemotherapy].
Ivanov S; Ivanov S; Khadzhiolov N
Akush Ginekol (Sofiia); 2004; 43(6):17-9. PubMed ID: 15669647
[TBL] [Abstract][Full Text] [Related]
13. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
[TBL] [Abstract][Full Text] [Related]
15. [Reassessment of second-look operations (SLO) in the treatment of ovarian cancer].
Ochiai K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1303-9. PubMed ID: 2730043
[TBL] [Abstract][Full Text] [Related]
16. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS
Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689
[TBL] [Abstract][Full Text] [Related]
17. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status.
Berek JS; Hacker NF; Lagasse LD; Poth T; Resnick B; Nieberg RK
Obstet Gynecol; 1984 Aug; 64(2):207-12. PubMed ID: 6539884
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years.
Mizutani K; Takeuchi S; Ohashi Y; Yakushiji M; Nishimura H; Takahashi T; Maruhashi T; Ueda K; Noda K; Watanabe Y; Kawana T; Terashima Y; Ochiai K; Goto S; Takaku F; Motoyoshi K
Oncol Rep; 2003; 10(1):127-31. PubMed ID: 12469157
[TBL] [Abstract][Full Text] [Related]
20. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]